Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune conditions, offering ...

Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade reflects a turnaroun...

Biocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...

Biocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 40868.42 Crore) operating in Pharmaceuticals ...

Biocon Ltd., incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 37404.69 Crore) operating in Pharmaceuticals ...

Biocon stock broke out from a Symmetrical Triangle pattern last week on the monthly charts, which has opened room for it to head higher and...

Biocon Ltd. key Products/Revenue Segments include Bio Pharmaceuticals, Other Operating Revenue, Waste and Sale of services for the year end...

Biocon's shares surged by 8% on Tuesday due to strong Q4 earnings growth. Net profit grew by 31% to INR 313 crore with 57% YoY growth in co...

As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when an in...

Biocon, incorporated in the year 1978, is a Large Cap company (having a market cap of Rs 44314.15 crore) operating in Pharmaceuticals secto...

The $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...

ANSM has raised deficiencies concerning two biosimilar products intended in the treatment of cancer and one intended for diabetes.

The stock price has priced in all the near-term positives arising from the business — leaving little room for any risks.

Investors must adopt stock-specific approach as valuations have turned expensive on pharma counters, says Joshi in an interview to ET Now.

Bullish on Biocon, recommend it even now before a dip: Mehraboon Irani.

The stock has been in an uptrend this week and has moved nearly 5% higher, while for the month of November Biocon surged over 16%.

Those who have been holding on to this stock for a long time, it has been a bit of a underperformer if you see in the last 1-1.5 years. So ...